Cite
HARVARD Citation
Cameron, D. et al. (n.d.). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet oncology. 18 (7), pp. 929-945. [Online].